Raagini Jawa

Raagini Jawa

Auto-generated profile, based on publicly available information

Raagini Jawa

University of Pittsburgh School of Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2024 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
RJRaagini Jawa
Raagini Jawa
SISamia Ismail
Samia Ismail
MSMargaret Shang
Margaret Shang
SMStephen Murray
Stephen Murray
CMCristina Murray-Krezan
Cristina Murray-Krezan
JLJane M. Liebschutz
Jane M. Liebschutz
Exposure to xylazine has been associated with wounds distinct from typical injection-related skin and soft tissue infections. We sought to understand drug use and wound care practices, and treatment experiences of people who use drugs (PWUD) in a high-prevalence area of xylazine adulteration. In August 2023, we surveyed adult PWUD reporting at least one past-year drug use-related wound across three Massachusetts syringe service programs. Using a representative illustration, participants indicated if they had experienced a xylazine wound in the past 90 days. We compared demographic, drug use factors, wound care, and medical treatment experiences among those with and without xylazine wounds. We also conducted additional content analysis of open-ended responses. Of the 171 respondents, 87 % (n=148) had a xylazine wound in the past 90 days. There were no statistically significant demographic differences between those with and without xylazine wounds. Among those primarily injecting (n=155), subcutaneous injection was nearly ten times more likely among people with xylazine wounds. For those with xylazine wounds (n=148), many engaged in heterogeneous wound self-treatment practices, and when seeking medical care, 74 % experienced healthcare stigma and 58 % had inadequate pain and withdrawal management. People with self-identified xylazine wounds were more likely to engage in subcutaneous injection and faced several barriers seeking medical wound treatment. Programs serving people exposed to xylazine should work to support safer injection practices, including alternatives to injecting and improving access to high-quality, effective wound care. Further study is warranted to understand the causes, promoters, and prevention of xylazine-related wounds.

20 February 2024 in Substance use & addiction journal
Verified
Journal Article
Closed access
RJRaagini Jawa
Raagini Jawa
SMStephen Murray
Stephen Murray
SBSamantha Blakemore
Samantha Blakemore
AVAlicia S. Ventura
Alicia S. Ventura
THTavita Hristova
Tavita Hristova
CLColleen LaBelle
Colleen LaBelle
Novel adulterants and synthetic substances are rapidly infiltrating the US drug supply causing new clinical harms. There is an urgent need for responsive education and training to address these evolving harms and mitigate new risks. Since 2020, xylazine, a veterinary tranquilizer, has become increasingly common in the illicit opioid supply, especially alongside fentanyl. Training and technical assistance (TTA) programs employing an adaptive model can quickly disseminate emerging information and provide the tools to respond effectively. We describe our TTA program’s experience developing and delivering virtual instructor-led xylazine training to a diverse group of addiction care professionals. The training objectives included the following: (1) introducing epidemiologic trends, pharmacology, and existing literature related to xylazine; (2) reviewing xylazine-associated harms and management; and (3) discussing harm reduction strategies related to xylazine use. We conducted 14 training sessions between October 2022 and July 2023, which were attended by over 2000 individuals across 49 states. We review our experience developing innovative training content and managing flexible training logistics and highlight our lessons learned, including targeting multidisciplinary professionals, leveraging online synchronous delivery methods, and a need for sustainable funding for TTA programs.

15 April 2025 in Substance use & addiction journal
Verified
Journal Article
Closed access
MSMargaret Shang
Margaret Shang
IHIlana Hull
Ilana Hull
JLJane M. Liebschutz
Jane M. Liebschutz
MAMichael Abesamis
Michael Abesamis
MLMichael Lynch
Michael Lynch
RJRaagini Jawa
Raagini Jawa
The evolving unregulated drug supply in the United States has led to an unprecedented rise in xylazine-adulterated synthetic opioid use-related morbidity and mortality, of which Pennsylvania shoulders a disproportionate burden. People experiencing these xylazine harms who seek acute medical care require complex clinical management, multidisciplinary coordination, and appropriate linkage to outpatient care. We describe our experience leading a hospital-wide multidisciplinary xylazine workgroup from February to June 2024 to collaboratively develop time-sensitive clinical protocols on inpatient management of patients exposed to xylazine. Workgroup participants were organized into three subgroups: (1) toxicology screening and harm reduction; (2) withdrawal management; and (3) inpatient wound care management and linkage to outpatient wound care. We summarize our implementation process and clinical protocol recommendations of each subgroup and highlight important cross-cutting issues related to the changing drug supply, standardized patient and provider educational tools, care coordination, and next steps.

2 November 2023 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
MSMargaret Shang
Margaret Shang
BTBrent Thiel
Brent Thiel
JLJane M. Liebschutz
Jane M. Liebschutz
KKKevin L. Kraemer
Kevin L. Kraemer
AFAriana Freund
Ariana Freund
RJRaagini Jawa
Raagini Jawa
Background: The rising rates of drug use-related complications call for a paradigm shift in the care for people who use drugs. While addiction treatment and harm reduction have historically been siloed in the US, co-location of these services in office-based addiction treatment (OBAT) settings offers a more realistic and patient-centered approach. We describe a quality improvement program on integrating harm reduction kits into an urban OBAT clinic. Methods: After engaging appropriate stakeholders and delivering clinician and staff trainings on safer use best practices, we developed a clinical workflow for universal offering and distribution of pre-packaged kits coupled with patient-facing educational handouts. We assessed: (1) kit uptake with kit number and types distributed; and (2) implementation outcomes of feasibility, acceptability, appropriateness, and patient perceptions. Results: One-month post-implementation, 28% (40/141) of completed in-person visits had at least one kit request, and a total of 121 kits were distributed. Staff and clinicians found the program to be highly feasible, acceptable, and appropriate, and patient perceptions were positive. Conclusions: Incorporating kits in OBAT settings is an important step toward increasing patient access and utilization of life-saving services. Our program uncovered a significant unmet need among our patients, suggesting that kit integration within addiction treatment can improve the standard of care for people who use drugs.

23 July 2024 in Journal of Addiction Medicine
Verified
Journal Article
Open access
RJRaagini Md Jawa
Raagini Md Jawa
SBSamantha Blakemore
Samantha Blakemore
SMStephen Mph Murray
Stephen Mph Murray
AVAlicia S. Ventura
Alicia S. Ventura
THTavita Bs Hristova
Tavita Bs Hristova
CLColleen MSN LaBelle
Colleen MSN LaBelle
Objectives: As xylazine increasingly adulterates the unregulated opioid supply, people who use drugs (PWUD) are more likely to experience sequalae from xylazine. Given xylazine exposure is consistently associated with development of wounds which can heal with medically directed wound care, we sought to understand the level of preparedness and ability of front-line addiction professionals who interact with PWUD to provide wound care treatment. Methods: We administered a 26-item online survey assessing participant and organizational characteristics, level of wound care training, ability to test for xylazine and treat xylazine-associated wounds, and funding and billing characteristics to a national sample of addiction professionals using a listserv of over 11,000 individuals. Results: We had a response rate of 12.8% in which 1,280 met eligibility criteria and completed the survey, with the majority (23.7%) being nurses. While nearly all participants had cared for patients who had experienced any xylazine-associated harms, less than half (43.6%) had cared for patients with xylazine wounds and 43.4% had any training or certification in wound care, including 26.9% of physicians. Although 75.9% of participants had access to wound care supplies, just 19.5% provided wound care services onsite. Conclusions: Most addiction professionals, especially physicians, lack wound care training and do not provide onsite treatment for drug-associated wounds at the organizational level. There is a critical need to bridge this gap in knowledge and build capacity to provide evidence-based wound care services to PWUD in areas impacted by xylazine adulteration.

17 March 2026 in Substance use & addiction journal
Verified
Journal Article
Closed access
TRTessa Rife-Pennington
Tessa Rife-Pennington
JBJenna L. Butner
Jenna L. Butner
KHKatherine Hill
Katherine Hill
BDBeth Dinges
Beth Dinges
MHMinh Q. Ho
Minh Q. Ho
JCJohn Curran
John Curran
Background: Harm reduction services fulfill a critical need in reducing the negative consequences associated with the overdose crisis. However, many current evidence-based harm reduction services—such as syringe service programs—have access barriers including limited hours or the need for face-to-face interactions to help serve people who use drugs (PWUD). Issue: To complement such traditional services, overcome barriers, and bridge gaps, harm reduction vending machines (HRVMs) are increasingly being used to offer PWUD low-barrier, 24-hour access to harm reduction supplies, such as naloxone, drug-checking strips, condoms, and more. Evidence from around the world, and more recently in the United States, demonstrates that HRVMs not only provide anonymous no- or low-cost supplies to PWUD, but also do so in ways that overcome key barriers such as stigma, cost, and transportation, while also increasing accessibility and acceptability among PWUD. Perhaps most notably, HRVMs can do all of this while remaining cost-efficient, highly accessible, and adaptable to community needs. Recommendations: Accordingly, the Association for Multidisciplinary Education and Research in Substance Use and Addiction supports funding and research for the broader application of HRVMs, alongside the creation of national implementation guidance and federal and state policy alignment, to ensure that communities across the United States can access these crucial harm reduction services.